Function Health Prescription and Intake Process: A Critical Review

What Function Health Is and How the Intake Process Works

Function Health is a lab-first telehealth company. It is not a compounding pharmacy, a single drug, or a supplement brand. Members pay an annual subscription, receive a requisition for a blood draw at a Quest Diagnostics location, and get a structured dashboard report with clinician commentary layered on top of standard lab values.

The intake sequence generally runs: sign up and complete a health history questionnaire, schedule a draw at a Quest site, review results through the dashboard, and book a follow-up consultation if a prescription or further workup looks warranted.

The health history questionnaire covers current medications, family history, chronic diagnoses, and symptoms. It is not diagnostic by itself; it gives a clinician context for interpreting the numbers. If a reviewing clinician identifies a lab value that meets a recognized treatment threshold, a prescription can be issued electronically without a separate in-person visit. If the finding is borderline or asymptomatic, the more common outcome is a recommendation for lifestyle change, repeat testing, or referral, not a prescription.

The blood draw

Quest Diagnostics operates a large national network of patient service centers and is CLIA-certified, meaning it operates under the federal quality standard for clinical laboratories administered by the Centers for Medicare and Medicaid Services. Members visit a participating Quest site with their requisition code; the sample is then processed at a Quest facility.

Dashboard and clinician sign-off

Results populate a dashboard that flags each value against a reference range, with a plain-language explainer. Function Health states that a licensed physician or nurse practitioner reviews each panel before release. That claim describes the platform's stated process; HealthRX.com has not independently audited how much time or scrutiny each review receives, and no published third-party audit of this workflow is available as of this writing.

What Function Health Actually Prescribes

Function Health does not run its own pharmacy and does not restrict prescriptions to a proprietary formulary. Prescriptions issued through the platform are meant to follow standard clinical pathways, the same ones a primary care physician or endocrinologist would use.

Thyroid medications

Hypothyroidism is common in the U.S. adult population, though exact prevalence estimates vary by the study population and the diagnostic cutoff used; a precise figure should not be quoted without checking current epidemiologic literature. Function Health's panel includes TSH, free T4, and free T3. Levothyroxine is the standard first-line treatment for overt hypothyroidism under American Thyroid Association guidance. Subclinical hypothyroidism (a TSH modestly above normal, with normal free T4) is a judgment call in mainstream endocrinology, not an automatic prescription, and that same discretion should apply on this platform as it would in any clinic.

Testosterone replacement therapy

The panel includes total and free testosterone, SHBG, LH, and FSH. Diagnosing male hypogonadism requires both a low testosterone level on repeat morning measurement and consistent symptoms, per Endocrine Society guidance; a single low value on one draw is not sufficient by itself. When both criteria are met, testosterone cypionate injections, topical gels, or other FDA-approved formulations are standard options. For women, the panel includes DHEA-S, estradiol, and progesterone; menopausal hormone therapy decisions should follow current North American Menopause Society guidance and an individualized risk discussion, not a lab value alone.

Metabolic and cardiometabolic medications

This assessment measures fasting glucose, insulin, HbA1c, and lipid levels. We apply American Diabetes Association Standards of Care for diabetes identification via HbA1c and initial metformin therapy. Statin recommendations for high LDL-C align with ACC/AHA cardiovascular risk guidance, using individualized LDL-C targets based on risk rather than one cutoff for all members. Members who qualify for GLP-1 receptor agonists like semaglutide or tirzepatide can access these medications if they meet FDA-approved criteria for obesity or weight management (typically BMI 30 or above, or BMI 27 or above with a relevant comorbid condition). These eligibility requirements reflect standard obesity medicine practice and are not unique to Function Health.

Other findings

Vitamin D deficiency, iron deficiency, and B12 deficiency identified on the panel can lead to a prescription-strength supplement or standard treatment when values are low enough to warrant it under Endocrine Society or comparable clinical guidance.

None of the above is a substitute for individualized dosing guidance from a treating clinician. Readers should not use this article to self-diagnose or self-dose based on a lab number.

Is Function Health Legitimate? Separating Regulatory Standing From Clinical Evidence

Legitimacy here has two distinct layers, and they should not be conflated.

Regulatory standing. Function Health's clinicians are described as licensed in the states where they practice, operating under state telehealth and medical practice laws. Labs are processed through Quest Diagnostics, a CLIA-certified lab network. This regulatory structure resembles other physician-supervised telehealth companies; it is not a workaround of physician oversight, since every result is reviewed by a licensed clinician before release, unlike pure self-pay lab-ordering services that hand back raw results with no interpretation.

Clinical validity of the panel. Many of the individual markers on the panel have decades of outcomes data behind them: HbA1c, LDL-C, TSH, creatinine, and hsCRP are all used routinely in mainstream medicine with established treatment thresholds. Other markers common on "longevity" panels carry weaker or more conditional evidence. IGF-1, for example, has shown a J-shaped association with mortality in observational data, meaning both very low and very high levels associate with more risk, which limits how much a single asymptomatic measurement can tell a patient without clinical context. The Endocrine Society does not recommend routine screening for growth hormone-axis abnormalities in adults without specific clinical indicators. Inflammatory markers such as hsCRP relate to chronic disease risk partly through diet-driven, low-grade inflammatory processes sometimes described in the nutrition literature as meta-inflammation (Nutrition and meta-inflammation, 2022); this is background mechanism, not a claim that Function Health's specific panel or thresholds have been validated in a trial.

The "optimal range" framing. Function Health presents some results against tighter "optimal" targets rather than only the standard laboratory reference range (the middle of a general population distribution). For LDL-C, guideline bodies do set explicit, tighter, risk-stratified targets for higher-risk patients, so a tighter target is not unreasonable there. For many other markers, "optimal" ranges reflect observational association rather than a tested treatment target, and members should ask their reviewing clinician to be explicit about which category a given number falls into before treating it as actionable.

What is established, what is plausible, what is not established

• Established: guideline-defined thresholds for thyroid, glycemic, lipid, and testosterone treatment decisions are the same whether a clinician sees them through Function Health or a conventional clinic.
• Plausible but unproven: broader, more frequent biomarker testing catches some treatable abnormalities earlier than an annual physical would. This is biologically plausible and consistent with how the included markers behave clinically, but it has not been tested as a bundled screening strategy against hard outcomes.
• Not established: that testing 100-plus markers as a package, tracking "biological age," or targeting non-guideline "optimal" ranges changes all-cause mortality or major disease incidence. No trial evidence available to HealthRX.com supports that claim, and the U.S. Preventive Services Task Force has not evaluated most of these markers as population screening tools.

How Much Does Function Health Cost

As publicly listed in 2025, the base membership is $499 per year, said to cover two annual blood draws, lab fees with Quest Diagnostics, dashboard access, and clinician review. Prescriptions are billed separately at standard pharmacy prices. The membership is not covered by insurance but is described as HSA/FSA eligible. Pricing, panel size, and included services change over time; verify current terms directly with Function Health before relying on any specific figure.

Function Health Versus Alternatives

Costs and panel sizes for competitor platforms change; treat the comparison as directional rather than a current price quote, and verify each platform's site before publishing a specific number.

For readers who want a longitudinal relationship with one physician rather than a large one-time panel, a Direct Primary Care practice can order comparable labs and prescribe, at a different cost structure. For readers whose primary care physician already orders lipids, HbA1c, TSH, and a metabolic panel annually, the marginal value of a broad add-on panel is smaller than for someone without that relationship.

Public Claims Versus What the Evidence Actually Shows

The table below separates what Function Health states publicly from what current evidence establishes. It is a comparison of claim types to evidence tiers, not a verdict on the company, and it should not be read as an endorsement or a rejection of the service.

What Members and Clinicians Report

Function Health has not published peer-reviewed outcomes data as a company. Publicly visible reviews on consumer platforms have generally skewed positive, with common praise for panel breadth and dashboard clarity, and common criticism about the cost of add-ons and limited real-time clinician access in the standard tier. HealthRX.com has not independently verified aggregate review scores, review authenticity, or the demographics of reviewers, so specific star ratings are not reproduced here; readers should check current reviews directly on the platforms where they appear.

Clinician opinion on comprehensive baseline panels is genuinely split. Preventive and functional medicine physicians tend to see value in a broad annual baseline for motivated, engaged patients. Physicians oriented toward value-based, guideline-based care question whether markers beyond standard preventive panels change management often enough in asymptomatic people to justify the added cost. Both positions are represented in mainstream clinical practice, and neither is settled by trial evidence specific to Function Health.

When to Use This Platform, and When Not To

Function Health is not built for urgent or acute problems. Chest pain, shortness of breath, signs of a severe allergic reaction, suicidal thinking, or any symptom that feels like an emergency needs immediate in-person or emergency care, not a scheduled lab draw and asynchronous dashboard review. The platform also does not replace an ongoing primary care relationship for people managing chronic disease, since it does not coordinate hospital care, manage acute illness, or provide the continuity a primary care physician offers across visits.

Frequently Asked Questions

References

• The Role of Nutrition on Meta-inflammation: Insights and Potential Targets in Communicable and Chronic Disease Management (2022). https://pubmed.ncbi.nlm.nih.gov/36258149/

Note for editorial and medical review: the source draft this article was built from contained direct quotations attributed to specific guideline documents and several precise statistics (prevalence figures, relative risk reductions, star ratings) tied to PubMed identifiers that could not be verified against the cited papers in this pass. Those quotations and precise figures have been removed or converted to general, unlinked descriptions of guideline positions pending confirmation of the correct primary source by a qualified reviewer.